<DOC>
	<DOCNO>NCT00673361</DOCNO>
	<brief_summary>This research study test `` chemo-switch '' strategy melanoma , use biochemotherapy initially shrink tumor switch daily low-dose chemotherapy ( temozolomide ) together sorafenib . The purpose study find effect ( good bad ) biochemotherapy follow temozolomide plus sorafenib melanoma .</brief_summary>
	<brief_title>Pilot Trial `` Chemo-Switch '' Regimen Treat Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Must histologically cytologically confirm melanoma locally advance metastatic . Cutaneous , mucosal , ocular , unknown primary melanoma eligible . Must measurable disease , define RECIST least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20mm conventional technique &gt; 10mm spiral CT scan . May receive prior radiation therapy one nonindex lesion ( prior radiation index lesion allowable progression irradiate lesion demonstrate , progression define increase 20 % large diameter ) and/or one prior vaccine therapy metastatic disease . Prior adjuvant therapy IFN alpha2b , vaccine , and/or granulocytemacrophage colonystimulating factor ( GMCSF ) permit . At least 4 weks must elapse since completion prior therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Patients must normal organ marrow function define : leukocyte &gt; 3,000/uL ( microliters ) absolute neutrophil count &gt; 1,500/uL platelet &gt; 100,000/uL total bilirubin &lt; 2.0mg/dL AST ( Aspartate transaminase ) ( SGOT ) /ALT ( Alanine transaminase ) ( SGPT ) &lt; 2.5 X institutional upper limit normal creatinine &lt; 1.8mg/dL If &gt; 50 year age one cardiac risk factor , must demonstrate normal exercise stress test , stress thallium test , comparable cardiac ischemia evaluation . Must least 2 week major surgery free active infection require antibiotic . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . Women must demonstrate negative pregnancy test prior initiation protocol therapy . Ability understand willingness sign write informed consent form . Prior chemotherapy , cytokine therapy ( include IL2 IFN alpha ) , antibody therapy metastatic disease . Prior vaccine therapy permit . May currently receive antineoplastic treatment , include chemotherapy , biologic response modifier , radiation , vaccine , investigational agent . History brain metastasis . Autoimmune disorder could result lifethreatening complication set IFN alpha IL2 treatment . History sensitivity E. coliderived product . Concurrent use corticosteroid medical condition likely require use systemic corticosteroid . A seizure disorder currently require antiepileptic medication . Uncontrolled intercurrent illness include , limited , hypertension , active infection require antibiotic therapy , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Evidence bleed diathesis . Currently therapeutic anticoagulation . Prophylactic anticoagulation ( lowdose warfarin ) venous arterial access device allow provided PT , PTT ( Partial Thromboplastin Time ) , international normalize ratio ( INR ) normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>